A phase I clinical trial of COM902 in advanced malignancies
Phase of Trial: Phase I
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs COM 902 (Primary)
- Indications Cancer
- Focus Adverse reactions
- 04 Nov 2019 According to a Compugen media release, this study is planned to be conducted at multiple centers in the United States and site selection activities are currently underway. The company plans to initiate this study in early 2020.
- 04 Nov 2019 According to a Compugen media release, the U.S. Food and Drug Administration has cleared an investigational new drug (IND) application for COM902 for advanced malignancies.
- 29 Nov 2018 New trial record